Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

St. Jude Medical Applauds MADIT-CRT Trial
St. Jude Medical, Inc. (NYSE: STJ) commends the efforts of investigators in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). The early results of the trial indicate that early intervention with CRT-D therapy can slow a patient"s progression from early stage heart failure (NYHA Class I-II) to late stage heart failure (NYHA Class III-IV).
generic viagra online
'Life Force' Linked To Body's Ability To Withstand Stress
Our ability to withstand stress-related, inflammatory diseases may be associated, not just with our race and sex, but with our personality as well, according to a study published in the July issue of the journal Brain, Behavior and Immunity. Especially in aging women, low levels of the personality trait extraversion may signal that blood levels of a key inflammatory molecule have crossed over a threshold linked to a doubling of risk of death within five years.
News of the day
Nonin Medical Announces FDA Clearance For Its Next-Generation Regional Oximetry System
Nonin Medical, Inc., a leading innovator of noninvasive physiological monitoring solutions, announced FDA clearance for its Model 7600 Regional Oximetry System. Introduced in June 2009 at the European Society of Anaesthesiology (ESA) conference in Milan, Italy, the innovative Model 7600 offers real-time monitoring of cerebral oxygenation for patients at risk of ischemia.
Nutrition

Sepracor Pharmaceuticals Ltd Withdraws Its Marketing Authorisation Application For Lunivia (eszopiclone)

The European Medicines Agency has been formally notified by Sepracor Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Lunivia (eszopiclone), 2 and 3 mg tablets. Lunivia was expected to be used for the treatment of insomnia, including difficulty falling asleep, nocturnal awakening or early awakening in adults, usually for short-term duration. The application for the marketing authorisation for Lunivia was submitted to the Agency on 23 July 2007. In October 2008, Lunivia received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending that the medicine be granted a marketing authorisation. However, the CHMP recommended that the medicine should not be granted "new active substance" status. Following a re÷¬examination procedure at the request of the applicant, the CHMP confirmed its previous opinion in February 2009. At the time of withdrawal, the application was pending the adoption of a marketing authorisation decision by the European Commission. In its official letter, the company stated that the withdrawal of the application was based on the CHMP"s recommendation that Lunivia should not be regarded as containing a new active substance, and that the commercial viability of launching the product in the European Union was compromised. More information about Lunivia and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 26-29 May 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. The press release from the October 2008 meeting can be found here. 3. The summary of the positive opinion from October 2008 can be found here. EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009